Our study is the first prospective study to compare and clarify the different roles of FGF21, CK18 and CK18 fragment in early identification and monitoring of NAFLD patients in one cohort. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.